Langerhans cell number is a strong and independent prognostic factor for head and neck squamous cell carcinomas

Oral Oncology

Volumn 62, Issue , 2016, Pages 1-10

  Kindt, Nadège ^a   Descamps, Géraldine ^a   Seminerio, Imelda ^a   Bellier, Justine ^a,e   Lechien, Jérôme R ^a   Pottier, Charles ^b   Larsimont, Denis ^c   Journé, Fabrice ^a,c   Delvenne, Philippe ^b   Saussez, Sven ^a,d  

^a UNIVERSITY OF MONS   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c JULES BORDET INSTITUTE   (Belgium)

^d UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^e UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

HNSCC; HPV; Langerhans cell; Multivariate analysis; Prognosis

Indexed keywords

ALCOHOL; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA;

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL COUNT; CONTROLLED STUDY; DYSPLASIA; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LANGERHANS CELL; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; TOBACCO; VIRUS DETECTION; WART VIRUS; ALPHAPAPILLOMAVIRUS; HEAD AND NECK TUMOR; ISOLATION AND PURIFICATION; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL ANALYSIS; VIROLOGY;

ALPHAPAPILLOMAVIRUS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; LANGERHANS CELLS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84987984776     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2016.08.016     Document Type: Article

References (33)

1. [1] Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., Global cancer statistics. CA Cancer J Clin 61 (2011), 69–90, 10.3322/caac.20107.
2. [2] Gillison, M.L., Koch, W.M., Capone, R.B., Spafford, M., Westra, W.H., Wu, L., et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92 (2000), 709–720.
3. [3] Buckley, L., Gupta, R., Ashford, B., Jabbour, J., Clark, J.R., Oropharyngeal cancer and human papilloma virus: evolving diagnostic and management paradigms. ANZ J Surg, 2015, 10.1111/ans.13417.
4. [4] Ang, K.K., Harris, J., Wheeler, R., Weber, R., Rosenthal, D.I., Nguyen-Tân, P.F., et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363 (2010), 24–35, 10.1056/NEJMoa0912217.
5. [5] Hong, A.M., Dobbins, T.A., Lee, C.S., Jones, D., Harnett, G.B., Armstrong, B.K., et al. Human papillomavirus predicts outcome in oropharyngeal cancer in patients treated primarily with surgery or radiation therapy. Br J Cancer 103 (2010), 1510–1517, 10.1038/sj.bjc.6605944.
6. [6] Rischin, D., Young, R.J., Fisher, R., Fox, S.B., Le, Q.-T., Peters, L.J., et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol Off J Am Soc Clin Oncol 28 (2010), 4142–4148, 10.1200/JCO.2010.29.2904.
7. [7] Nygård, M., Aagnes, B., Bray, F., Møller, B., Mork, J., Population-based evidence of increased survival in human papillomavirus-related head and neck cancer. Eur J Cancer Oxf Engl 2012:48 (1990), 1341–1346, 10.1016/j.ejca.2012.03.014.
8. [8] Duray, A., Descamps, G., Decaestecker, C., Remmelink, M., Sirtaine, N., Lechien, J., et al. Human papillomavirus DNA strongly correlates with a poorer prognosis in oral cavity carcinoma. Laryngoscope 122 (2012), 1558–1565, 10.1002/lary.23298.
9. [9] Rosenquist, K., Wennerberg, J., Annertz, K., Schildt, E.-B., Hansson, B.G., Bladström, A., et al. Recurrence in patients with oral and oropharyngeal squamous cell carcinoma: human papillomavirus and other risk factors. Acta Otolaryngol (Stockh) 127 (2007), 980–987, 10.1080/00016480601110162.
10. [10] Lee, L.-A., Huang, C.-G., Liao, C.-T., Lee, L.-Y., Hsueh, C., Chen, T.-C., et al. Human papillomavirus-16 infection in advanced oral cavity cancer patients is related to an increased risk of distant metastases and poor survival. PLoS ONE, 7, 2012, e40767, 10.1371/journal.pone.0040767.
11. [11] Ward, M.J., Thirdborough, S.M., Mellows, T., Riley, C., Harris, S., Suchak, K., et al. Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. Br J Cancer 110 (2014), 489–500, 10.1038/bjc.2013.639.
12. [12] Young, D., Xiao, C.C., Murphy, B., Moore, M., Fakhry, C., Day, T.A., Increase in head and neck cancer in younger patients due to human papillomavirus (HPV). Oral Oncol 51 (2015), 727–730, 10.1016/j.oraloncology.2015.03.015.
13. [13] Combes, J.-D., Franceschi, S., Role of human papillomavirus in non-oropharyngeal head and neck cancers. Oral Oncol 50 (2014), 370–379, 10.1016/j.oraloncology.2013.11.004.
14. [14] Descamps, G., Karaca, Y., Lechien, J.R., Kindt, N., Decaestecker, C., Remmelink, M., et al. Classical risk factors, but not HPV status, predict survival after chemoradiotherapy in advanced head and neck cancer patients. J Cancer Res Clin Oncol, 2016, 10.1007/s00432-016-2203-7.
15. [15] Castellsagué, X., Alemany, L., Quer, M., Halec, G., Quirós, B., Tous, S., et al. HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients. J Natl Cancer Inst, 2016, 108, 10.1093/jnci/djv403.
16. [16] Merad, M., Sathe, P., Helft, J., Miller, J., Mortha, A., The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol 31 (2013), 563–604, 10.1146/annurev-immunol-020711-074950.
17. [17] de Avila Erica, Dorigatti, de Molon, Rafael Scaf, de Almeida Lawall, Melaine, Consolaro, Renata Bianco, Consolaro, Alberto, Increased of langerhans cells in smokeless tobacco-associated oral mucosal lesions. Scopemed, 2012 [accessed May 18, 2016] .
18. [18] Barrett, A.W., Cruchley, A.T., Williams, D.M., Oral mucosal langerhans’ cells. Crit Rev Oral Biol Med 7 (1996), 36–58, 10.1177/10454411960070010301.
19. [19] Nguyen, N., Bellile, E., Thomas, D., McHugh, J., Rozek, L., Virani, S., et al. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head Neck, 2016, 10.1002/hed.24406.
20. [20] Duray, A., Descamps, G., Decaestecker, C., Sirtaine, N., Gilles, A., Khalifé, M., et al. Human papillomavirus predicts the outcome following concomitant chemoradiotherapy in patients with head and neck squamous cell carcinomas. Oncol Rep 30 (2013), 371–376, 10.3892/or.2013.2415.
21. [21] Budczies, J., Klauschen, F., Sinn, B.V., Győrffy, B., Schmitt, W.D., Darb-Esfahani, S., et al. Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS ONE, 7, 2012, e51862, 10.1371/journal.pone.0051862.
22. [22] Dieu-Nosjean, M.C., Massacrier, C., Homey, B., Vanbervliet, B., Pin, J.J., Vicari, A., et al. Macrophage inflammatory protein 3alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors. J Exp Med 192 (2000), 705–718.
23. [23] Lasisi, T.J., Oluwasola, A.O., Lasisi, O.A., Akang, E.E., Association between langerhans cells population and histological grade of oral squamous cell carcinoma. J Oral Maxillofac Pathol JOMFP 17 (2013), 329–333, 10.4103/0973-029X.125177.
24. [24] Albuquerque, R.L.C., Miguel, M.C.C., Costa, A.L.L., Souza, L.B., Correlation of c-erbB-2 and S-100 expression with the malignancy grading and anatomical site in oral squamous cell carcinoma. Int J Exp Pathol 84 (2003), 259–265.
25. [25] Narayanan, B., Narasimhan, M., Langerhans cell expression in oral submucous fibrosis: an immunohistochemical analysis. J Clin Diagn Res JCDR 9 (2015), ZC39–ZC41, 10.7860/JCDR/2015/12608.619.
26. [26] Costa, N.L., Gonçalves, A.S., Martins, A.F.L., Arantes, D.A.C., Silva, T.A., Batista, A.C., Characterization of dendritic cells in lip and oral cavity squamous cell carcinoma. J Oral Pathol Med, 2015, 10.1111/jop.1238 n/a-n/a.
27. [27] Gallo, O., Libonati, G.A., Gallina, E., Fini-Storchi, O., Giannini, A., Urso, C., et al. Langerhans cells related to prognosis in patients with laryngeal carcinoma. Arch Otolaryngol Head Neck Surg 117 (1991), 1007–1010.
28. [28] Yilmaz, T., Gedikoglu, G., Celik, A., Onerci, M., Turan, E., Prognostic significance of Langerhans cell infiltration in cancer of the larynx. Otolaryngol-Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg 132 (2005), 309–316, 10.1016/j.otohns.2004.04.018.
29. [29] Goldman, S.A., Baker, E., Weyant, R.J., Clarke, M.R., Myers, J.N., Lotze, M.T., Peritumoral CD1a-positive dendritic cells are associated with improved survival in patients with tongue carcinoma. Arch Otolaryngol Head Neck Surg 124 (1998), 641–646.
30. [30] Guess, J.C., McCance, D.J., Decreased migration of langerhans precursor-like cells in response to human keratinocytes expressing human papillomavirus type 16 E6/E7 is related to reduced macrophage inflammatory protein-3α production. J Virol 79 (2005), 14852–14862, 10.1128/JVI.79.23.14852-14862.2005.
31. [31] Caberg, J.-H., Hubert, P., Herman, L., Herfs, M., Roncarati, P., Boniver, J., et al. Increased migration of Langerhans cells in response to HPV16 E6 and E7 oncogene silencing: role of CCL20. Cancer Immunol Immunother CII 58 (2009), 39–47, 10.1007/s00262-008-0522-5.
32. [32] Jiang, B., Xue, M., Correlation of E6 and E7 levels in high-risk HPV16 type cervical lesions with CCL20 and Langerhans cells. Genet Mol Res GMR 14 (2015), 10473–10481, 10.4238/2015.September.8.8.
33. [33] Gonçalves, A.S., Costa, N.L., Arantes, D.A.C., de Cássia Gonçalves Alencar, R., Silva, T.A., Batista, A.C., Immune response in cervical lymph nodes from patients with primary oral squamous cell carcinoma. J Oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol 42 (2013), 535–540, 10.1111/jop.12039.